This is a preview of subscription content, log in via an institution to check access.
References
American Cancer Society. Cancer Facts & Figures 2005 [online]. Available from URL: http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf [Accessed 2005 Feb 21]
Cristofanilli M, Krishnamurthy S, Guerra L, et al. Advexin (Ad5CMV-53) combined with docetaxel and doxorubicin as induction chemotherapy: significant efficacy of a novel gene-therapy approach for patients with locally advanced breast cancer [abstract 1058, poster]. Breast Cancer Research and Treatment 2004; 88 Suppl. 1: 61
Rossner D, Hollwitz B, Schaff C, et al. The combination of paclitaxel and the farnesyltransferase inhibitor SCH 66336 in the treatment of metastatic breast cancer. A phase I/II study. Breast Cancer Research and Treatment 2004; 88 Suppl. 1: 64
Sparano JA, Vahdat L, Moulder S, et al. Phase I-II trial of tipifarnib plus cyclophosphamide and doxorubicin in patients with metastatic and locally advanced breast cancer: clinical and molecular effects [abstract 1067]. Breast Cancer Research and Treatment 2004; 88 Suppl. 1: 64
Melisko ME, Peethambaram P, Rinn K, et al. Immunotherapy targeting HER2/Neu: results from phase 1 studies of APC8024 in women with metastatic breast cancer [abstract 6079, poster]. Breast Cancer Research and Treatment 2004; 88 Suppl. 1: 247
Kobayashi S, Boggon TJ, Dayaram J, et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 2005; 352(8): 786–92
Rights and permissions
About this article
Cite this article
Recent R&D Highlights. Pharmaceutical & Diagnostic Innovation 3, 17–19 (2005). https://doi.org/10.1007/BF03262526
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03262526